We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

53 hedge funds and large institutions have $207M invested in Arbutus Biopharma in 2017 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more capital invested

Capital invested by funds: $133M → $207M (+$74.3M)

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

6% more funds holding

Funds holding: 50 → 53 (+3)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 15

7.04% less ownership

Funds ownership: 67.03% → 60% (-7%)

17% less call options, than puts

Call options by funds: $141K | Put options by funds: $169K

Holders
53
Holders Change
+3
Holders Change %
+6%
% of All Funds
1.32%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
12
Increased
15
Reduced
15
Closed
8
Calls
$141K
Puts
$169K
Net Calls
-$28K
Net Calls Change
-$322K

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$961K
2
SSA
Schonfeld Strategic Advisors
New York
+$535K
3
Morgan Stanley
Morgan Stanley
New York
+$404K
4
RI
RTW Investments
New York
+$241K
5
UBS Group
UBS Group
Switzerland
+$224K

Top Sellers

1
LTFS
Ladenburg Thalmann Financial Services
Florida
-$15.1M
2
SM
Sabby Management
Florida
-$895K
3
Axa
Axa
France
-$881K
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$757K
5
KPF
K2 Principal Fund
Ontario, Canada
-$538K
Name Holding Trade Value Shares
Change 		Change in
Stake
QF
1
QVT Financial
New York
$99.3M – – –
RI
2
RTW Investments
New York
$32.7M +$241K +56,457 +1%
Primecap Management
3
Primecap Management
California
$24.7M +$171K +40,000 +1%
LTFS
4
Ladenburg Thalmann Financial Services
Florida
$13.3M -$15.1M -3,526,054 -67%
D.E. Shaw & Co
5
D.E. Shaw & Co
New York
$10.9M +$83.7K +19,576 +1%
Bank of Montreal
6
Bank of Montreal
Ontario, Canada
$5.29M -$86.9K -20,325 -2%
Axa
7
Axa
France
$3.57M -$881K -205,999 -26%
Morgan Stanley
8
Morgan Stanley
New York
$2.61M +$404K +94,353 +29%
KPF
9
K2 Principal Fund
Ontario, Canada
$1.55M -$538K -125,839 -33%
Point72 Asset Management
10
Point72 Asset Management
Connecticut
$1.39M +$961K +224,655 New
BBA
11
Baker Bros. Advisors
New York
$1.12M – – –
CS
12
Credit Suisse
Switzerland
$1.09M +$389 +91 +0.1%
Renaissance Technologies
13
Renaissance Technologies
New York
$996K -$212K -49,629 -24%
Deutsche Bank
14
Deutsche Bank
Germany
$811K -$218K -50,938 -28%
Victory Capital Management
15
Victory Capital Management
Texas
$801K -$15.2K -3,550 -3%
OAM
16
Oxford Asset Management
United Kingdom
$778K +$175K +40,963 +49%
SSA
17
Schonfeld Strategic Advisors
New York
$775K +$535K +125,000 New
Hudson Bay Capital Management
18
Hudson Bay Capital Management
Connecticut
$732K -$757K -177,000 -60%
Invesco
19
Invesco
Georgia
$700K +$63.5K +14,837 +15%
TI
20
Telemetry Investments
New York
$682K -$464K -108,400 -50%
Vanguard Group
21
Vanguard Group
Pennsylvania
$488K +$5.22K +1,221 +2%
Barclays
22
Barclays
United Kingdom
$470K +$12.6K +2,941 +4%
UBS Group
23
UBS Group
Switzerland
$326K +$224K +52,451 +45,610%
Mackenzie Financial
24
Mackenzie Financial
Ontario, Canada
$247K – – –
SC
25
Scotia Capital
Ontario, Canada
$196K +$43.4K +10,150 +47%
1
2 3

ABUS Hedge Fund Activity: Q3 2017 in Review

53 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2017, worth a combined $207M — up 56% from $133M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ABUS positions and 8 closed out — a net gain of 4 holders — while 15 added to existing stakes and 15 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $961K. The largest seller was Ladenburg Thalmann Financial Services, cutting an estimated $15.1M.

  • 53 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2017, up from 50 in Q2 2017.
  • Funds reported $207M of Arbutus Biopharma stock for Q3 2017, up 56% quarter-over-quarter.
  • 12 funds opened new Arbutus Biopharma positions in Q3 2017 and 8 closed out, a net change of +4 holders.
  • The largest Arbutus Biopharma buyer in Q3 2017 was Point72 Asset Management, an estimated $961K added.
  • The largest Arbutus Biopharma seller in Q3 2017 was Ladenburg Thalmann Financial Services, an estimated $15.1M sold.

Based on aggregated 13F filings for Q3 2017.